First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer,...
13 Junho 2019 - 7:45AM
XOMA Corporation (Nasdaq: XOMA) announced today that gevokizumab,
an anti-IL1β monoclonal antibody that XOMA discovered and initially
developed, is now actively progressing in a Novartis oncology
development program. The antibody candidate is being
evaluated to determine the appropriate dose, as well as preliminary
safety and efficacy, in combination with standard of care
anti-cancer therapies in patients with metastatic colorectal
cancer, metastatic gastroesophageal cancer, and metastatic renal
cell carcinoma. Recently the first patient was dosed with
gevokizumab in the dose-finding portion of the study.
“This is an important milestone both for XOMA and for
gevokizumab. Gevokizumab was XOMA’s primary focus for almost
a decade,” commented Jim Neal, Chief Executive Officer of
XOMA. “We are pleased to see gevokizumab re-enter clinical
development under the guidance of Novartis, and we are grateful to
the patients and their families who have agreed to participate in
the clinical trial.”
More information about the gevokizumab clinical study can be
found at ClinicalTrials.gov, study identifier
NCT03798626.
Gevokizumab is an investigational compound. Efficacy and
safety have not been established. There is no guarantee that
gevokizumab will become commercially available.
About XOMA CorporationXOMA has built a
significant portfolio of products that are licensed to and being
developed by other biotechnology and pharmaceutical
companies. The Company’s portfolio of partner-funded programs
spans multiple stages of the drug development process and across
various therapeutic areas. Many of these licenses are the
result of XOMA’s pioneering efforts in the discovery and
development of antibody therapeutics. The Company’s
royalty-aggregator business model includes acquiring additional
licenses to programs with third-party funding. For more
information, visit www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
creating additional value for the stockholders and cash sufficiency
forecast. These statements are based on assumptions that may
not prove accurate, and actual results could differ materially from
those anticipated due to certain risks inherent in the
biotechnology industry, including those related to the fact that
our product candidates subject to out-license agreements are still
being developed, and our licensees may require substantial funds to
continue development which may not be available; we do not know
whether there will be, or will continue to be, a viable market for
the products in which we have an ownership or royalty interest; if
the therapeutic product candidates to which we have a royalty
interest do not receive regulatory approval, our third-party
licensees will not be able to market them. Other potential
risks to XOMA meeting these expectations are described in more
detail in XOMA's most recent filing on Form 10-K and in other SEC
filings. Consider such risks carefully when considering
XOMA's prospects. Any forward-looking statement in this press
release represents XOMA's views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. XOMA disclaims any obligation to
update any forward- looking statement, except as required by
applicable law.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development.
Investor contact: Juliane Snowden Oratorium
Group, LLC +1 646-438-9754 jsnowden@oratoriumgroup.com
Media contact: Kathy Vincent KV Consulting
& Management +1 310-403-8951 kathy@kathyvincent.com
XOMA (NASDAQ:XOMA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
XOMA (NASDAQ:XOMA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024